Organization | EuroVacc Foundation

EuroVacc Foundation Report issue

Foundation Phase 1 Phase 2

Founded: Amsterdam Netherlands (2002)

Organization Overview

First Clinical Trial

2007

NCT00490074

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

EuroVacc Foundation

Active Ingredients

Drugs in Phase 2 Trials (9)

dna-c (1 trial)

dna-hiv-pt123 (5 trials)

emtricitabine (emtriva) (1 trial)

hiv glycoprotein cn54gp140 vaccine (1 trial)

mva hiv-b (1 trial)

nyvac-c (1 trial)

tenofovir (viread) (1 trial)

tenofovir alafenamide (genvoya) (1 trial)

vedolizumab (entyvio) (1 trial)

Drugs in Phase 1 Trials (7)

aidsvax b/e (4 trials)

cn54gp140/mpla-l (1 trial)

drep-hiv-pt1 (1 trial)

nyvac-b (1 trial)

nyvac-hiv-pt1 (2 trials)

nyvac-hiv-pt4 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 1)

Communicable Diseases (Phase 2)

HIV Infections (Phase 2)

Infections (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 9
# of Trial APIs: 16